Mutual Fund Details

Nippon India Pharma Fund Direct-IDCW Reinvestment

Equity Pharma

NAV

₹131.8897

as on 29 Sep 2023, 11:25 PM

₹2.2581(1.74%)

Last Change

Schemes Managed By

Sailesh Raj Bhan

Fund Manager

Investment Performance

would have given a return of

₹1,10,871

₹1,21,647

₹1,56,301

₹1,60,648

Bank Account

Fixed Deposit

Regular Mutual Fund

This Fund on Paytm Money

This Mutual Fund

₹60,648

Profit (absolute return)

60.65%

in the last

max

+1% Higher Returns

With Direct Plans on Paytm Money

Investment Returns

In the last 3 months

11.47%

In the last 6 months

30.82%

In the last 1 year

25.99%

In the last 3 years

60.65%

In the last 5 years

132.82%

In the last 10 years

425.76%

Absolute Returns

CAGR

Scheme Riskometer

low

low to moderate

moderate

moderately high

high

very high

Investors understand that their principal will be at very high risk

Scheme Information

Nippon India Pharma Fund Direct-IDCW Reinvestment

as of 31 Aug 2023, 05:30 AM

₹5,544.92 Cr

Scheme Asset Size

Fund Type

Open-End

Exit Load

Exit load of 1% if redeemed within 1 month.

1.01%

Expense Ratio

Plan

Dividend

3.23%

Cash Holding

Benchmark

S&P BSE Healthcare Total Return Index

Scheme Document

View

Benchmark

S&P BSE Healthcare Total Return Index

Exit Load

Exit load of 1% if redeemed within 1 month.

Scheme Document

View

Sectors Holding in this Mutual Fund

as on 31 Aug 2023

Sort By

Value

Sector

Healthcare

95.87%

₹5,315.91 Cr

Chemicals

0.88%

₹48.80 Cr

Others

3.25%

₹180.21 Cr

Sectors Holding in this Mutual Fund

as on 31 Aug 2023

Sort By

Value

Sector

Healthcare

95.87%

₹5,315.91 Cr

Chemicals

0.88%

₹48.80 Cr

Others

3.25%

₹180.21 Cr

Companies Holding in this Mutual Fund

as on 31 Aug 2023

Sort By

Value

Company

Sun Pharmaceutical Inds. Ltd.

13.14%

₹728.60 Cr

Lupin Ltd.

7.53%

₹417.53 Cr

Cipla Ltd.

6.80%

₹377.05 Cr

Dr. Reddy's Laboratories Ltd.

5.56%

₹308.30 Cr

Gland Pharma Ltd.

4.71%

₹261.17 Cr

Others

62.26%

₹3,452.26 Cr

View All

Companies Holding in this Mutual Fund

as on 31 Aug 2023

Sort By

Value

Company

Sun Pharmaceutical Inds. Ltd.

13.14%

₹728.60 Cr

Lupin Ltd.

7.53%

₹417.53 Cr

Cipla Ltd.

6.80%

₹377.05 Cr

Dr. Reddy's Laboratories Ltd.

5.56%

₹308.30 Cr

Gland Pharma Ltd.

4.71%

₹261.17 Cr

Others

62.26%

₹3,452.26 Cr

View All

Funds in this Category

This fund's returns:

17.14%

Return Duration

3 Years

SBI Healthcare Opportunities Fund Direct Plan-Growth

Nippon India Pharma Fund Direct-Growth

Mirae Asset Healthcare Fund Direct - Growth

About Nippon India Pharma Fund Direct-IDCW Reinvestment

Nippon India Pharma Fund Direct-IDCW Reinvestment is a Equity mutual fund scheme from Nippon India Mutual Fund. This scheme was launched on Invalid date and is currently managed by its fund manager Sailesh Raj Bhan. It has an AUM of ₹5,544.92 Crores and the latest NAV decalared is ₹131.890 as on 03 Oct 2023 at 12:37 am.

Nippon India Pharma Fund Direct-IDCW Reinvestment scheme return performance in last 1 year is 25.99%, in last 3 years is 60.65% and 454.22% since scheme launch. The min. SIP amount to invest in this scheme is ₹100.